Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles matching "Precursor Cell Lymphoblastic Leukemia-Lymphoma"

Clinical trialUNITERAREMay 6

New Recruiting Trial: A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Researchers are looking for children and young adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) who have gone into remission after receiving CAR-T cell therapy. This study will use advanced genetic testing to monitor how well the patient's immune system recovers after treatment and help doctors decide on the best follow-up care plan.

WHY IT MATTERSThis trial offers a personalized monitoring approach for ALL patients in remission after CAR-T therapy, potentially reducing unnecessary treatments while catching early signs of relapse through genetic testing rather than standard methods alone.
→ You can act on thisB-cell acute lymphoblastic leukemiaB lineage acute lymphoblastic leukemia
Clinical trialUNITERAREApr 5

New Recruiting Trial: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.

WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
→ You can act on thisacute myeloid leukemiaacute lymphoblastic leukemiachronic myeloid leukemia

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases